As mRNA therapeutics move into new disease areas, the next challenge is turning promising science into scalable, reproducible development processes.
Two Milestones, One Bigger Story
The mRNA field continues to expand beyond its early focus on vaccines. Recent developments from Abogen Biosciences highlight how the technology is being explored for more complex therapeutic applications — and why global pharmaceutical companies are paying attention.
Two milestones stand out.
- September 18, 2026: Research on Abogen’s ABO2203 was published in Cell. The investigational therapy uses lipid nanoparticle (LNP)-formulated mRNA to encode a CD19-targeting T-cell engager, an approach designed to deplete B cells. In an early human study involving three patients with refractory immune thrombocytopenia, the researchers reported rapid B-cell depletion and sustained clinical responses during follow-up. These findings are promising, but the small study size means further research is needed to establish safety and efficacy.
- October 2, 2026: Abogen announced a licensing and option agreement with Novartis to advance its mRNA-encoded T-cell engager and explore additional RNA programs. The agreement was reported to be worth up to approximately $7.8 billion, including $575 million in upfront payment.
Together, these developments point to an important shift: mRNA is increasingly being explored not just as a way to deliver an antigen, but as a platform for producing therapeutic proteins in the body.
Why mRNA Is Expanding Beyond Vaccines
Traditional biologics often require the production, purification, and delivery of complex proteins. With mRNA-based approaches, the therapeutic instructions can instead be delivered to cells, which then produce the encoded protein.
This creates opportunities across several therapeutic areas, including:
- Immuno-oncology: Exploring mRNA-encoded immune-engaging proteins and other immune-modulating approaches.
- Autoimmune diseases: Investigating targeted immune-cell depletion and potential immune reprogramming strategies.
- Protein replacement: Exploring transient expression of therapeutic proteins that may be difficult to deliver directly.
The approach also introduces its own challenges. Therapeutic performance depends on more than the encoded sequence: mRNA design, delivery systems, transcript integrity, purity, and protein expression all influence the final outcome.
That is why advances in mRNA therapeutics need to be matched by advances in the processes used to develop and manufacture them.
From a Promising Molecule to a Scalable Platform
A successful early-stage candidate is an important milestone. Building a repeatable development platform, however, requires a broader set of capabilities.
Three areas deserve particular attention.
1. Transcription efficiency and RNA integrity
In vitro transcription (IVT) is a foundational step in mRNA production. T7 RNA polymerase, nucleotide substrates, buffer composition, and reaction conditions can all influence transcription performance.
Double-stranded RNA (dsRNA), a potential process-related impurity, is another important consideration because it can contribute to unwanted innate immune activation. Selecting suitable polymerases and optimizing reaction conditions can help manage dsRNA formation while maintaining RNA integrity.
2. Capping and functional performance
The 5′ cap plays an important role in mRNA stability, translation initiation, and interactions with cellular RNA-sensing pathways.
Developers can choose between different approaches, including enzymatic capping after transcription and co-transcriptional capping. The appropriate strategy depends on the construct, process requirements, and desired product attributes.
3. Purification and quality control
After transcription and capping, residual DNA templates, enzymes, nucleotides, and dsRNA may need to be controlled or removed.
Purification and analytical testing help developers assess product quality and understand how process changes affect the final RNA material. As programs advance, consistency, traceability, and appropriate quality documentation become increasingly important.
The key takeaway: A scalable mRNA platform is not defined by one enzyme or one reaction. It depends on how the entire workflow performs as an integrated process.
Supporting the mRNA Workflow with Yeasen
Yeasen provides reagents and enzymes supporting key stages of mRNA development, from template preparation and IVT to capping and purification.
The portfolio includes T7 RNA polymerase, NTP substrates, supporting enzymes, and selected GMP-grade materials with quality documentation. For capping, developers can choose between two-step enzymatic capping and LZCap™ one-pot co-transcriptional capping, depending on their workflow needs.
By providing materials across these core steps, Yeasen supports researchers in developing and optimizing mRNA production workflows, from early-stage research toward more demanding process requirements.
Looking Ahead: Platform Thinking Will Matter
The Abogen–Novartis agreement does not guarantee the clinical success of ABO2203 or other mRNA candidates. It does, however, reflect growing interest in RNA technologies with the potential to support multiple therapeutic programs.
For mRNA developers, the opportunity extends beyond designing the next promising molecule. It also means building workflows that deliver the required quality, reproducibility, and scalability as programs advance.
The next stage of mRNA innovation will depend not only on what mRNA can encode, but also on how reliably it can be produced.
Related Products
|
Product |
Cat. No. |
Key Application |
|
10628ES |
IVT with reduced dsRNA formation |
|
|
10629ES |
GMP-grade mRNA synthesis |
|
|
10133ES |
Nucleotide substrates for IVT |
|
|
10621ES |
Protects RNA from RNase degradation |
|
|
10614ES |
Enzymatic 5′ capping |
|
|
10612ES |
Enzymatic cap methylation |